NF-κB

Where the papers sit

72 papers from the last 6 months study NF-κB directly · updated from PubMed 11 Oct 2026

• Inflammation Across Organ Systems

  NF-κB-linked inflammatory signaling is being examined across metabolic, pulmonary, neural, intestinal, vascular and cancer settings. TLR4, NLRP3, gut microbiota metabolites and macrophage state recur as regulators of tissue injury and immune function. Interventions range from probiotics and plant compounds to BMSCs, nanomaterials and CAR-T products. The shared direction is pathway-guided inflammation control, but disease contexts and endpoints remain highly varied.

  24 papers · 33.3%

• Oxidative Stress and Macrophage Inflammation

  ROS control is being paired with immune reprogramming rather than pursued as simple antioxidant therapy. Nrf2/NF-κB modulation, JNK signaling, PAK1-dependent dendritic-cell activation and macrophage glycolysis recur across asthma, atherosclerosis, fibrosis and allergic disease. Ferroptosis and neutrophil extracellular traps add cell-death mechanisms to the inflammatory network. Biomimetic nanoplatforms and plant-derived compounds are moving toward coordinated suppression of oxidative and immune injury.

  18 papers · 25%

• TLR4-Driven Inflammatory Disease

  TLR4/MyD88/NF-κB signaling is emerging as a common therapeutic entry point across metabolic, neurologic, renal, reproductive and infectious disease models. Natural compounds, nanomodulators and repurposed drugs are used to reduce IL-1β, TNF-α and IL-6, often while shifting macrophages toward an M2 state. Pyroptosis, oxidative stress and epithelial barrier damage extend the pathway beyond cytokine release. Evidence is predominantly preclinical, leaving target selectivity and clinical translation open.

  17 papers · 23.6%

• STAT3–NF-κB Inflammatory Signaling

  STAT3–NF-κB pathway crosstalk is being targeted to restrain inflammation, tissue damage and abnormal cell differentiation. NFATc1 links this circuitry to osteoclast formation and postmenopausal osteoporosis, while iNOS and STAT3 recur in colitis and liver injury. Dual inhibitors, engineered nanoplatforms and small-molecule analogues are being explored in cancer, wound healing and inflammatory disease. The cluster supports pathway convergence, but therapeutic effects remain context-dependent and largely preclinical.

  7 papers · 9.7%

• Ischemia-Reperfusion Neuroinflammation

  Ischemia-reperfusion injury is being targeted through coordinated control of neuroinflammation, mitochondrial stress and cell death. SIRT1 activation and AKT/NF-κB inhibition recur alongside TLR4/NF-κB–NLRP3 blockade. Astrocyte swelling, MMP9/AQP4 signaling, ferroptosis and glutamate-related injury are repeated endpoints. Most evidence remains preclinical, with electroacupuncture, natural compounds and siRNA delivery moving toward multi-pathway protection.

  6 papers · 8.3%